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Summary Cavitation (volume oscillations and collapse of gas bubbles), as generated by a co-administration of
shockwaves (SW) and microbubbles (SWB), induces cytotoxicity in vitro. Moreover, cavitation potentiates the
effects of Fluorouracil (FUra) on colon cancer cells. We aimed at reproducing such effects in vivo. A peritoneal
carcinomatosis was induced in BDIX rats by intraperitoneal (IP) injection of DHDK12PROb cells. Cavitation
was produced by various SW regimens (250 to 750SW) combined with bubbles (air/gelatin emulsion) infused
through an IP catheter. In two consecutive experiments, microtumours (day 3 after cell injection) were
submitted to various combinations of cavitation and/or Fluorouracil (FUra) and Cisplatinum (CDDP) at
either high or low doses. After 30 days, 100% of control animals were dead or presented carcinomatosis with
ascites, vs 60% after FUra 5 mg kg dy, day 4 through 8, and 0% after 250 SWB, day 4 and 6 + FUra
5 mg kg dy, day 4 through 8 (P<0.001); similar differences were found with CDDP. Survival after low dose
FUra + SWB was comparable to high dose FUra (25 mg kg dy day 4 through 8) and was improved as
compared to low-dose FUra alone. Only a high dose FUra + SWB schedule induced 40% long term (> 150
days) disease-free survival, but also a higher undesirable toxicity (40% toxic deaths within 1 month). It is
concluded that cavitation is cytotoxic in vivo and that it potentiates the effects of FUra and CDDP in this
animal model.
Most patients with digestive adenocarcinomas die from
metastasis. In the conventional therapeutic armamentarium,
only a few cytotoxic drugs, like 5-Fluorouracil (FUra), have
been shown to induce clinical response (Gastrointestinal
Tumor Study Group, 1984; Calabresi & Chabner, 1990;
Valeriote & Santelli, 1984) and only surgery is able to im-
prove survival in less than 10% of the patients with liver
metastasis (Nakamura et al., 1992; Registry of Hepatic
Metastases, 1988). New therapeutic instruments are thus
clearly needed to improve the prognosis of metastasis from
bowel malignancies. Despite disappointing results from
radiotherapy and conventional hyperthermia, physical
methods may be interesting as an alternative approach to, or
in combination with, chemotherapy. Biological effects of
acoustic waves, like high intensity ultrasound and shock
waves have been studied for many years (Flynn, 1964;
Church & Miller, 1983); while direct cytotoxic effects may
play a minor role, several studies have shown that damage is
caused to microvessels and endothelial cells, causing vascular
disruption as well as the production of free radicals, leading
to hypoxia and indirect toxicity to the affected tissue (Miller,
1987). It has also been demonstrated that the cytotoxicity of
shock waves was obtained mostly through acoustic cavita-
tion, which is the transitory volume oscillations of gas
microbubbles induced by rapidly varying pressure waves,
eventually resulting in the collapse of bubbles (Dear et al.,
1988). When a bubble collapses near an interface with a cell
membrane, such dramatic damage is inflicted to the cell as to
induce cell death (Delius et al., 1989; Miller, 1987; Miller et
al., 1991). However, the therapeutic potentialities of cavita-
tion have so far remained confined to in vitro experimental
studies and have not evolved toward clinical applications for
two reasons: (1) ultrasound was not able to induce cytotoxi-
city unless generated in vitro in specific experimental condi-
tions (Church & Miller, 1983); (2) technological facilities
were lacking for the in vivo application of focused acoustic
waves. The recent development of clinical applications of
acoustic waves to the treatment of urinary and biliary stones
offered solutions to the latter problem; to overcome the
former one, we used gas micro-bubbles infused into the
target area during an administration of shock waves. The
feasability of this technique was first demonstrated in the
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normal rabbit liver in vivo (Prat et al., 199la). Further
experiments with HT-29 cells in suspension and viable rat
colon peritoneal metastases treated in vitro showed that
cavitation could hinder cell proliferation and induce complete
tissue necrosis (Prat et al., 1991b). In a more recent study
(Prat et al., personal communication), the cytotoxicity of
FUra to HT-29 cells was greatly enhanced by a preliminary
exposure of the cells to cavitation, through potentially syner-
gistic mechanisms.
In the present study, we aimed at investigating the
relevance of cavitation to the treatment of a disseminated
digestive tumour in vivo.
Materials and methods
Cells
DHD K12 PROb cells (a gift from Pr Martin, INSERM
U252, Dijon, France) originated from a dimethyl-hydrazine-
induced rat colon carcinoma were cultured in Dulbecco's
modified Eagle's medium supplemented with 8% fetal calf
serum under 8% CO2. The cells were cultured to confluence
in 75cm2 flasks and detached after 12 days of culture by
2.5/1000 trypsin/0.2/1000 EDTA. Cell viability was assessed
before each use by trypan blue exclusion; it was always over
90%.
Animals
Male and female BD IX rats, syngeneic with DHD K12
PROb cells, were used in this study. The animals were aged 8
to 12 weeks and weighed 190 to 320 g. They were housed in a
temperature and light-controlled room and were fed ad
libitum.
Tumour induction
A peritoneal carcinomatosis was induced by the intra-
peritoneal injection of 1.5 106 trypan blue-negative DHD
K12 PROb cells diluted in 1.5 ml of culture medium.
Tumour take was 100%
Production ofcavitation and treatment ofthe animals
The rationale for the generation of shockwave cavitation was
as follows: shockwaves were produced by underwater spark
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discharge from an electro-hydraulic generator (Sonolith 3000,
Technomed International, Bron, France) producing a peak
positive pressure of 60 MPa at the focus; the focus, as deter-
mined by hydrophone pressure recordings (Bilaminar hydro-
phone, Marconi Research, UK), was a cylinder, 10 mm in
diameter by 18 mm in height. Shockwaves were focused on
the target area on the abdominal wall of the animal; simul-
taneously, gas microbubbles were produced from a mixture
of air and modified gelatin agitated by a rotating blade in a
sterile tight-closed tank and progressively infused into the
abdominal cavity through a peritoneal catheter during shock-
wave administration.
At the time scheduled for treatment, the rats were anaes-
thetised by an intra-peritoneal injection of sodium pentobar-
bital (0.1 ml kg-); a catheter (0.83 mm in internal diameter)
was inserted in the peritoneal cavity through a small incision
in the right flank of the animal; the catheter was positioned
so as to infuse the whole peritoneal cavity but preferentially
the upper anterior abdominal zone (large omentum) which is
the predominant and initial site of peritoneal carcinomatosis
in this model. Eventually, the catheter was tightly sutured to
the abdominal wall and the incision was closed.
Soon after the operation, the animal was positioned on a
purpose-built plexiglas set-up over the shockwave generator;
the set-up presented an opening in order to allow for the
penetration of the shock waves into the abdomen and to
protect the remainder of the animal from deleterious effects
of the shock waves to vital organs. (Figure 1). A phantom
shank was used to position the animal conveniently, i.e. so
that the upper abdominal area was irradiated by the focal
zone of the generator; the phantom was removed before
starting a session. Immediately after a treatment session, the
catheter was removed and the animal was allowed to recover;
in case of a second treatment session, the same abdominal
incision was used for the insertion of the catheter as for the
initial session.
Experimental design
Firstly, ('experiment I'), we wanted to assess the clinical
outcome of animals treated by cavitation alone or in com-
bination with chemotherapy when bearing microcarcino-
matosis. Six groups of nine to twelve rats each were assigned
to the following therapeutic schedules: (1) chemotherapy
alone administered at the stage of early microcarcinomatosis,
i.e. FUra (Fluorouracile, Roche Lab., Neuilly/Seine, France)
10 mg kg-' body weight IP, day 1 and 2 after tumour induc-
tion (a dose which, in previous experiments, had been shown
to induce 50% complete remissions); (2) 250 shockwaves with
bubbles only, in one session the third day after tumour
induction; (3) 500 shockwaves with bubbles only, in one
session the third day after tumour induction; (4) FUra
1Omg kg' body weight IP, day 1 and 2 followed by 250
shockwaves with bubbles day 3; (5) FUra 10 mg kg-' IP, day
1 and 2 followed by 500 shockwaves with bubbles day 3; (6)
controls. In this preliminary experiment, the only endpoint
used was the clinical status 30 days after tumour induction
(27 days after cavitation). The clinical status was assessed at
sacrifice on day 30 following a 3-class categorisation: class
A = absence of macroscopic peritoneal disease; class
B = presence of a mild macroscopic peritoneal carcino-
matosis, but clinical condition remained fair, without ascites;
class C = advanced disease with poor clinical condition and
hemorragic ascites or death of the animal before 30 days.
Secondly, in consideration of results from 'experiment IF, a
second set of experiments ('experiment II') was conducted
with the aim of investigating the interest of cavitation in
combination schedules with chemotherapy. We thus used
therapeutic schedules including two successive cavitation ses-
sions and two different drugs (FUra and Cisplatinum -
CDDP-). Drug schedules were reproduced from data
obtained by Chauffert et al. (personal communication). Eight
groups of five rats each were assigned to the following
schedules (day # refers to the time elapsed from tumour
induction to the date of therapy): (1) FUra alone, 25 mg kg-'
day 4 through 8; (2) FUra alone, 5 mg kg-' day 4 through 8;
(3) CDDP (Cisplatyl, Roger Bellon, France) 3 mg kg' day
4; (4) CDDP 0.5 mg kg-l day 4; (5) 250 Shockwaves + bub-
bles alone in two sessions at day 4 and 6; (6) 250 Shock-
waves + bubbles in two sessions at day 4 and 6 combined
with FUra, 5 mg kg-' day 4 through 8; (7) 250 Shockwaves-
+ bubbles in two sessions at day 4 and 6 combined with
CDDP 0.5 mgkg' day 4; (8) controls. The protocols are
summarised in Table I. The end points used were the clinical
outcome at day 30 as in 'experiment I' and the weight
: /-;F
Figure 1 Experimental set-up: (1) Under general anesthesia, the rat is placed upon a purpose-built plexiglas set-up; (2) The shock
wave generator focuses pressure waves onto the upper mesocolic area; (3) Gas micro-bubbles are infused during treatment through
an intra-peritoneal catheter.
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Table I The therapeutic protocols used in experiment II
4 5 6 7 8 Day 30
V
V V V V V
SFU 25 mgkg-' IP
Day 4+8
v v v v v
5FU 25 mg kg-' IP
Day 4+8
V V
Shock waves + bubbles
Day 4 & 6
V V
vvv V
Cis-platinum 3 mg kg-'
IP Day 4
V
Cis-platinum 0.5 mg kg-'
IP Day 4
V V
V
Autopsy
v
V
V
V
V
V
variation between day 0 and 30. A 1 cm portion of the small
intestine (jejunum) was systematically sampled for histology:
in each sample, the mean villus height and the mean number
of mitoses per villus were assessed on HPS-stained slices.
Thirdly, in order to assess survival and toxicity of com-
bined therapies, six additional groups of five to ten rats each
were assigned to the following schedules: (1) FUra alone,
25 mg kg-' day 4 through 8; (2) FUra alone, 5 mg kg-' day
4 through 8; (3) 250 Shockwaves + bubbles alone in two
sessions at day 4 and 6: (4) 250 Shockwaves + bubbles in two
sessions at day 4 and 6 combined with FUra, 5 mg kg-' day
4 through 8; (5) 250 Shockwaves + bubbles in two sessions at
day 4 and 6 combined with FUra, 25 mg kg-' day 4 through
8; (6) controls.
In all these experiments, each single experiment performed
on the same day included one animal from each group in
order to reduce inter-group variability.
Statistics: Survival was assessed by means of a Kaplan-
Meier's curve. Chi2 tests were used to compare clinical out-
comes between groups.
Results
All animals from these experiments recovered completely
within less than 24 h; in most animals treated with cavitation
(either 250 or 500 SWs), the presence of blood mixed with
non-resorbed emulsion was noted at removal of the catheter;
the presence of fresh blood in the faeces of 20% of the
animals treated with cavitation was also observed. However,
none of the animals presented further pathological features
which could be interpreted as toxic consequences of the
treatments during the first week post-therapy (e.g. diarrhoea,
rapid weight losses, gross modifications of the behaviour,
etc). No death was noted during the first week post-therapy,
in any of the groups. However in the survival study, the
group treated with high dose FUra and cavitation, in con-
trast with all others, presented 40% toxic deaths within the
first month. These animals died from starvation, without
ascites, never from developing carcinomatosis.
Clinical evaluation 30 days after adjuvant therapy
Experiment I The first protocol using single dose regimens
for both cavitation and chemotherapy showed that FUra
alone improved the outcome of the animals after 30 days of
follow-up, but was unable to induce complete remission in
more than 50% of the animals; cavitation alone did not
significantly improve the outcome as compared to controls;
the shockwave regimen (250 vs 500 SW) did not influence the
results and lastly, the combination of cavitation and FUra
suggested an improvement of the results as compared to
FUra alone but no significant difference was observed.
Experiment II The use of more sophisticated schedules with
intercalation of 2 cavitation sessions in a sequence of
chemotherapy, and the choice of more appropriate doses of
drugs yielded more significant results: if cavitation alone
could sterilise peritoneum in some 40% of the animals and
low doses of FUra or CDDP in 0%, high doses of FUra on
a 5 day schedule or CDDP in one high-dose injection could
achieve a 'clean abdomen' in 100% of the cases. On the other
hand, the combination of either low-dose FUra or low-dose
CDDP with cavitation was able to achieve the same result as
high-dose schedules of the drugs alone (Table II). The evolu-
tion of the body weight in the different groups between day 0
and 30 showed no gross difference, but a slight trend of
controls to a weight loss, in contrast with most other groups
which had steady or ascending curves (Figure 2).
Pathological evaluation 30 days after adjuvant therapy
Apart from the clinical assessment and classification, it
should be noted that in about 60% of the animals receiving
CDDP and 20% of those receiving FUra (in both
experiments I and II), the liver presented a whitish glossy
aspect due to a fibrous capsule; this feature was not
influenced by the exposure to cavitation.
The histological examination of jejunal villi from all
groups showed that the height of the villi was not influenced
by cavitation as well as by CDDP or FUra; however, the
number of mitoses per villus was more important in all
treated groups (cavitation and/or chemotherapy) than in con-
trol groups (normal and cancer controls): 2-6 as compared
to 1-2 mitoses per villus.
Survival after adjuvant therapy with FUra
Consistent with the results of different schedules on the
mid-term clinical outcome, it was observed that a low-dose
drug-alone schedule did not improve survival as compared to
controls, regardless to the drug used. Cavitation alone was
able to increase survival significantly with a 60% survival at
day 60 (as compared to 0% in controls and low-dose FUra).
A combination of cavitation and low-dose FUra prolonged
survival almost as much as high-dose FUra did; lastly, only
high dose FUra with cavitation induced long term disease-
free survivals (40%), but with early toxic deaths - see above
- (Figure 3).
Day 0
Controls
FUra 25
FUra
v
IP Injection of
1.5 106 cells
V
v
Cavitation (C)
C + FUra 5
CDDP 3
CDDP 0.5
C + CDDP 0.5
V
V
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Table II Classification of animals at autopsy 30 days after tumour induction,
depending on the early stage therapeutic protocol in Experiment II (see text for
classification). Numbers in the boxes: Top left = absolute number of animals; bottom
right (underlined) = percentage of animals
Clinical classification
at day 30
Treatment A B C
Controls 0 0 10 10 0 0 100 1
SW + bubbles 4 4 2 10 day 4 & 6 40 40 20
5FU alone 25mgkg-' 10 0 0 10 IP day 4+8 100 0 0
5FU alone 5mgkg- 0 4 6 10
IP day 4+8 0 40 60 <0.00I
SW + bubbles 10 0 0
day 4 + 8 & 5FU 5 10
mgkg'-I day 44.8 100 0 0
CDDP alone 3mgkg-' 10 0 0 10 day 4 ioo 0 0
CDDP alone 0.5mgkg-I 0 2 8 10
day 4 0 20 80 P<0.001
SW + bubbles 10 0 0
day 4+8 & 10
CDDP 0.5 mgkg-' day 4 100 0 0
44 10 26 80
Global Yates Chi2 test
P <0.01
350 - Discussion
300 -,
m2' 250 -
40'
0 200-
150 -
100
Day 0 Day 30
Figure 2 Weight variation between day 0 and 30 depending on
the therapeutic protocol (after removal of ascites, if necessary) -
experiment II-. Controls -A-, FUra 5 -*-, FUra 25
-El-, C -*-, C + FUra 5 -0-, CDDP 3 --, CDDP
0.5 -O-, C+CDDP 0.5 -A-.
100 - -
80 LX
, 60r ...
a~ 40
-
.L.
OL 20
-
0
0 50 100 150
Days
Figure 3 Survival of the animals depending on the early stage
therapeutic protocols. Controls, FUra 5 mg kg-'
day 4+8, FUra 25 mg kg-' day 4+8 . ...... 250 shock-
waves + bubbles, 250 shockwaves + bubbles + FUra
5 mg kg- ' 4+8, 250 shockwaves + bubbles + FUra
25 mg kg- ' day 4+8.
Several research groups have found some toxicity of shock-
waves to tumours in animal models (Oosterhof et al., 1991;
Russo et al., 1986; 1987). Others have shown that shock-
waves could enhance cytotoxicity when cells were shortly
incubated with the drugs during shock wave exposure (Gam-
bihler & Delius, 1992; Warlters et al., 1992). In previous
works, we showed that the combination of conventional
shockwaves with gas microbubbles could: (1) induce a block-
ade of the growth of human colon cells in culture and
eradicate cell proliferation from solid colic tumours treated in
vitro (Prat et al., 1991b); (2) potentiate the cytotoxicity of
FUra in HT-29 cells (Prat et al., personal communication).
The present work is a projection of these findings in an in
vivo model. The focal spot of the generator used is large
enough to irradiate most of the area of the large omentum,
where most cancer cells nest in this model; it was subse-
quently reasonable to expect some effects of cavitation on
the adhesion and invasion of early microcarcinomatosis in
that area. In experiment I, when challenged to a chemothera-
peutic schedule inducing a 50%-remission rate, cavitation,
either alone or combined with such a drug schedule, did not
exhibit a significant advantage on the outcome of the animals.
We deduced that an appropriate combination therapy schedule
should include more ofcavitation (i.e. two sessions instead of
one) and less ofchemotherapy (5 mg kg-' vs 10 mg kg-') and
be challenged to a 'drug-alone' schedule inducing a high
remission rate and at least a doubling of the survival time.
Under such conditions, it has been demonstrated that cavita-
tion potentiated FUra and CDDP on both the clinical out-
come in the mid-term and the survival (for FUra) in the long
term. While 100% remissions were obtained with certain
therapeutic schedules at day 30, some animals treated with
the same schedules still died within 5 months of follow-up.
This can be explained by the fact that cavitation, as well as
FUra, induces a blockade of the cell cycle and an accumula-
tion of cells in GO/GI (Prat et al., personal communication;
Valeriote & Santelli, 1984); we thus suggest that some cancer
cells, still present in the peritoneum at day 30, may re-enter
the cell-cycle or continue tumour growth at a slower rate.
I
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The survival curves show that in no case but the combination
of high dose FUra with cavitation was a survival observed
over 5 months after tumour induction. In the case of cavita-
tion, this may be interpreted as a result of an incomplete
irradiation which did not involve the whole abdominal
cavity, and subsequently allowed for some remnant cells to
progress to large tumours. Nevertheless, the combination of
high dose FUra with cavitation is a potentially curative
option, associated with a toxicity which is probably the
consequence of an intestinal impairment.
This contrasts with the relatively low incidence of toxicity
directly related to cavitation in all other groups: no animal
died post-operatively, the growth curve of the rats was not
significantly affected and most importantly, no toxic effect
was noted on the morphology and kinetics of the intestinal
epithelium 30 days after therapy.
Corroborated by the most recent results from other
laboratories on the anti-tumour effects of cavitation and
shockwaves (Oosterhof et al., 1991), we now consider cavita-
tion as a potential novel physical method for the treatment of
some cancers, probably in combination with systemic
therapies. However, the technique that we used in this study
to produce cavitation is still very rudimentary and is not
applicable to the man at its present stage of development.
Further improvements are needed to: (1) either enhance the
focusing of cavitation to obtain a selective tissue ablation in
a well-defined target or, on the contrary, to de-focus the
acoustic beam to achieve a large-field irradiation; (2) get rid
of the infusion of gas bubbles whose pharmacokinetics,
biodistribution and toxicity are not well understood, and
produce cavitation through purpose-built generators.
We thank Mr B. Chauffert from INSERM U252, Dijon, for
methodological advice and suggestions. Supported in part by the
Region Rhone-Alpes and an ARC grant, No. 6833.
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